M, M. (2024). Editorial Comment from Dr Miyake to Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART). International journal of urology : official journal of the Japanese Urological Association, 31(3), 273. https://doi.org/10.1111/iju.15384
Chicago Style (17th ed.) CitationM, Miyake. "Editorial Comment from Dr Miyake to Real-world Outcomes of Avelumab Plus Axitinib as First-line Therapy in Patients with Advanced Renal Cell Carcinoma in Japan: A multicenter, Retrospective, Observational Study (J-DART)." International Journal of Urology : Official Journal of the Japanese Urological Association 31, no. 3 (2024): 273. https://doi.org/10.1111/iju.15384.
MLA (9th ed.) CitationM, Miyake. "Editorial Comment from Dr Miyake to Real-world Outcomes of Avelumab Plus Axitinib as First-line Therapy in Patients with Advanced Renal Cell Carcinoma in Japan: A multicenter, Retrospective, Observational Study (J-DART)." International Journal of Urology : Official Journal of the Japanese Urological Association, vol. 31, no. 3, 2024, p. 273, https://doi.org/10.1111/iju.15384.
